Shares of Intra-Cellular Therapies Inc. (ITCI) are rising over 82% in pre-market today, after the company reported positive topline results from its Phase 3 clinical trial (Study 402) evaluating lumateperone as adjunctive therapy to lithium or valproate in the treatment of major depressive episodes associated with Bipolar I or Bipolar II disorder.

Create Account

Dark

chart

exchange

Check out our Level2View

Shares of Intra-Cellular Therapies Inc. (ITCI) are rising over 82% in pre-market today, after the company reported positive topline results from its Phase 3 clinical trial (Study 402) evaluating lumateperone as adjunctive therapy to lithium or valproate in the treatment of major depressive episodes associated with Bipolar I or Bipolar II disorder.

RTTNews | Sep 9, 2020 08:50AM EDT

08:49 Wednesday, September 9, 2020 (RTTNews.com) - Shares of Intra-Cellular Therapies Inc. (ITCI) are rising over 82% in pre-market today, after the company reported positive topline results from its Phase 3 clinical trial (Study 402) evaluating lumateperone as adjunctive therapy to lithium or valproate in the treatment of major depressive episodes associated with Bipolar I or Bipolar II disorder.

The stock has been trading in the range of $6.75 - $43.56 for the past one year, and closed Tuesday's trade at $18.43, up 38 cents or 2.11%. ITCI is currently trading at $33.64, up $15.21 or 82.53% in the pre-market session.

Read the original article on RTTNews ( https://www.rttnews.com/3127248/stock-alert-intra-cellular-therapies-shares-surge-82-in-early-trade.aspx)

For comments and feedback: contact editorial@rttnews.com

Copyright(c) 2020 RTTNews.com All Rights Reserved